Our Site Management Organisation is expanding the network of Medical Centres. Due to the huge demand for patient recruitment and procurement, we have opened a new site in Warsaw.
“The new space was created in response to the dynamic growth of our center and the increasing number of clinical trials we are conducting. Our goal is to further develop our research capabilities in Warsaw, while providing a better working environment and enhanced comfort for our study participants”. – Marta Jeka, Global SMO Head, Medicover Integrated Clinical Services.
Our new centre started operating right away, with the first patient visit this week.
The new facility strengthens our ability to run complex and large-scale studies, offering modern infrastructure for clinical trial operations. It provides dedicated areas for patient care and improves support for investigators, ensuring smooth trial execution in line with international standards.
“I would like to thank all our colleagues from the Warsaw Medical Centre (MICS Centrum Medyczne Warszawa ) and the great support from Medicover Healthcare for bringing this centre to life. Thanks to your dedication, this new centre will create opportunities for new patients to participate in clinical trials and contribute to the advancement of medicine.” – continues Marta Jeka.
For Sponsors, the Warsaw site offers access to a high-performing clinical research center, embedded within a network of research-ready sites with experienced investigators and staff. With proven patient recruitment capacity across multiple therapeutic areas, we create conditions that accelerate study timelines and improve overall trial performance.
Discover how our Clinical Research Network can support your next study
Highlights of Our Recent Recruitment Performance
- Selected as a partner and designated “Prime Site” by several top-five global CROs.
- Over 700 successfully completed studies, supported by high-quality execution and broad patient access.
- An average of 1,000 patients currently enrolled in ongoing clinical trials.
- Recruitment integrated with our central laboratory services, SMO network, and data management tools.
Global and Regional Recognitions
- Top global recruiter in a Phase III study for Systemic Lupus Erythematosus. (Top recruiter in systemic lupus, Medicover MICS enrolled the highest number of patients worldwide)
- Top five globally for patient randomization in a Sjögren’s Disease study involving 182 sites worldwide. (Top 5 Randomizing Sites Globally)
- Global top recruiter in a study on Seronegative Myasthenia Gravis, alongside leading centers in the USA, Germany, Spain, Norway, France, and China. (Learn more)
- Third in Europe and second in Poland in a Phase III randomized, double-blind, placebo-controlled study in active Sjögren’s Syndrome.
